Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the eighth most ...

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a patient ...

Cancer Research U.K. has launched a large, multicenter trial to test a new device for detecting Barrett's esophagus, a condition that puts sufferers at increased risk of developing cancer of the ...

The study, published in Gastroenterology, shows TissueCypher can increase the detection of Barrett’s esophagus (BE) patients with an initial diagnosis of low-grade dysplasia (LGD) who will progress to ...

Investigators at the Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test ...

This year, more than 22,000 Americans face a chilling diagnosis — esophageal cancer. Men are three to four times more likely to develop it. The odds? Less than a 20% chance of surviving five years.

FULLERTON, Calif. (KABC) -- The latest findings reveal esophageal cancer rates are up across the board. Many factors can raise your risk, including your line of work. A recently FDA-approved, ...

Exact Sciences has put forward positive data on its approach to screening for esophageal tumors and the disease’s precancerous conditions with a method that may allow patients to skip a sedated ...

BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry “We believe EsoGuard, the first and only commercially available diagnostic ...